Status:
TERMINATED
Renal Denervation for Resistant Hypertension
Lead Sponsor:
Baker Heart and Diabetes Institute
Conditions:
Hypertension
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
This is a study investigating the effectiveness of renal denervation in lowering blood pressure in people whose blood pressure is not adequately controlled despite treatment with 3 or more blood press...
Detailed Description
Previous studies have shown that the renal denervation procedure is safe and effective in reducing blood pressure in patients with resistant hypertension. A total of 100 participants with uncontrolled...
Eligibility Criteria
Inclusion
- systolic BP ≥140mmHg or ≥130mmHg for patients with diabetes
- concurrent treatment with ≥3 anti-hypertensive drugs
Exclusion
- renal artery anatomy ineligible for treatment
- eGFR \<15mL/min/1.73m2 (using Modification of Diet in Renal Disease (MDRD) calculation)
- female participants of childbearing potential must have negative pregnancy test prior to treatment
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01865240
Start Date
February 1 2012
End Date
October 1 2013
Last Update
November 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baker IDI Heart & Diabetes Inst
Melbourne, Victoria, Australia, 3004